Showing results (1-10 of 38) with videos related to
Sort By:
Pageof 4
Current Opinion in Molecular Therapeutics|August 3, 2010
Adenovirus-based therapy for prostate cancerMaria Ekblad, Gunnel HalldénMethods in Molecular Biology (Clifton, N.J.)|September 28, 2011
Adenoviral gene expression and replication in human tumor explant modelsGunnel HalldénHuman Gene Therapy|May 26, 2010
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenograftsSuresh Radhakrishnan, Enrique Miranda, Maria Ekblad, et al.Oncolytic Virotherapy|September 1, 2016
Oncolytic adenovirus-mediated therapy for prostate cancerKatrina Sweeney, Gunnel HalldénExpert Opinion on Therapeutic Targets|August 14, 2012
Oncolytic virotherapy with modified adenoviruses and novel therapeutic targetsGunnel Halldén, Giuseppe PortellaCancer Letters|July 9, 2018
Advances in oncolytic adenovirus therapy for pancreatic cancerCallum Baird Nattress, Gunnel HalldénHuman Gene Therapy|July 14, 2012
Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer ModelsVirginie Adam, Maria Ekblad, Katrina Sweeney, et al.Frontiers in Molecular Biosciences|July 11, 2022
Targeting Triple Negative Breast Cancer With Oncolytic AdenovirusesGabriela Green-Tripp, Callum Nattress, Gunnel HalldénOncotarget|February 13, 2016
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11Constantia Pantelidou, Gioia Cherubini, Nick R Lemoine, et al.The Journal of Biological Chemistry|October 27, 2004
Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activityMike Lee, Margono Hadi, Gunnel Halldén, et al.Pageof 4